ZA201708325B - Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof - Google Patents
Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereofInfo
- Publication number
- ZA201708325B ZA201708325B ZA2017/08325A ZA201708325A ZA201708325B ZA 201708325 B ZA201708325 B ZA 201708325B ZA 2017/08325 A ZA2017/08325 A ZA 2017/08325A ZA 201708325 A ZA201708325 A ZA 201708325A ZA 201708325 B ZA201708325 B ZA 201708325B
- Authority
- ZA
- South Africa
- Prior art keywords
- polysaccharide
- adsorption
- improving
- methods
- vaccine formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/116—Polyvalent bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2185MU2015 | 2015-06-08 | ||
| PCT/IB2016/053265 WO2016199003A1 (en) | 2015-06-08 | 2016-06-03 | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201708325B true ZA201708325B (en) | 2019-05-29 |
Family
ID=57503115
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/08325A ZA201708325B (en) | 2015-06-08 | 2017-12-07 | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10729780B2 (enExample) |
| EP (1) | EP3302542A4 (enExample) |
| JP (2) | JP7258463B2 (enExample) |
| KR (2) | KR102876828B1 (enExample) |
| CN (1) | CN107847571A (enExample) |
| AU (2) | AU2016276269B2 (enExample) |
| CA (1) | CA2988366C (enExample) |
| CO (1) | CO2017012628A2 (enExample) |
| EA (1) | EA201792470A1 (enExample) |
| IL (1) | IL256118B (enExample) |
| MX (1) | MX2017015985A (enExample) |
| MY (1) | MY187461A (enExample) |
| PE (1) | PE20180460A1 (enExample) |
| PH (1) | PH12017502244A1 (enExample) |
| SA (1) | SA517390495B1 (enExample) |
| WO (1) | WO2016199003A1 (enExample) |
| ZA (1) | ZA201708325B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102143534B1 (ko) | 2015-05-04 | 2020-08-12 | 화이자 인코포레이티드 | B군 스트렙토코쿠스 폴리사카라이드-단백질 접합체, 접합체를 생산하는 방법, 접합체를 포함하는 면역원성 조성물, 및 그의 용도 |
| US10729780B2 (en) * | 2015-06-08 | 2020-08-04 | Serum Institute Of India Private Ltd. | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
| CN106822884B (zh) * | 2016-12-28 | 2021-04-30 | 北京民海生物科技有限公司 | 一种多价肺炎球菌荚膜多糖结合疫苗的制备方法 |
| US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
| IL267709B2 (en) | 2016-12-30 | 2025-04-01 | Vaxcyte Inc | Polypeptide-antigen conjugates with unnatural amino acids |
| CN110392690B (zh) * | 2017-02-24 | 2024-01-30 | 默沙东有限责任公司 | 肺炎球菌缀合物疫苗制剂 |
| US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
| CA3074706A1 (en) * | 2017-09-07 | 2019-03-14 | Merck Sharp & Dohme Corp. | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
| EP3720483B1 (en) | 2017-12-06 | 2025-11-19 | Merck Sharp & Dohme LLC | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| CN108524926B (zh) * | 2018-06-29 | 2021-06-29 | 康希诺生物股份公司 | 一种多价肺炎球菌结合疫苗的制剂组合及其应用 |
| GB201818517D0 (en) * | 2018-11-13 | 2018-12-26 | Univ Liverpool John Moores | Nanoparticles and uses thereof |
| EP3897705A2 (en) | 2018-12-19 | 2021-10-27 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
| CA3142692A1 (en) * | 2019-06-05 | 2020-12-10 | Merck Sharp & Dohme Corp. | An immunogenic serotype 35b pneumococcal polysaccharide-protein conjugate and conjugation process for making the same |
| US12473379B2 (en) | 2019-09-06 | 2025-11-18 | Serum Institute Of India Private Limited | Method for obtaining purified bacterial polysaccharides |
| CN113607939B (zh) * | 2021-08-05 | 2024-10-22 | 艾美探索者生命科学研发有限公司 | 肺炎球菌多糖结合疫苗各型结合原液吸附率测定方法 |
| CN115006522B (zh) * | 2022-06-16 | 2025-08-22 | 北京智飞绿竹生物制药有限公司 | 一种双价痢疾结合物组合疫苗的制备方法 |
| CA3232076A1 (en) * | 2023-04-17 | 2025-04-14 | Serum Institute Of India Private Limited | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2059692C (en) | 1991-01-28 | 2004-11-16 | Peter J. Kniskern | Pneumoccoccal polysaccharide conjugate vaccine |
| DK1587537T3 (da) * | 2003-01-30 | 2012-07-16 | Novartis Ag | Injicerbare vacciner mod multiple meningococ-serogrupper |
| AU2004263135B2 (en) * | 2003-08-06 | 2010-11-25 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Polysaccharide-protein conjugate vaccines |
| EP1871411A4 (en) * | 2005-04-18 | 2010-07-21 | Novartis Vaccines & Diagnostic | EXPRESSION OF HEPATITIS B VIRUS SURFACE ANTIGEN FOR VACCINE MANUFACTURE |
| JP5792920B2 (ja) * | 2005-12-22 | 2015-10-14 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
| WO2007071786A2 (en) * | 2005-12-23 | 2007-06-28 | Glaxosmithkline Biologicals Sa | Conjugate vaccines |
| TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| EA200901578A1 (ru) * | 2007-06-26 | 2010-08-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae |
| TW201136603A (en) | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
| US20130273098A1 (en) * | 2010-12-10 | 2013-10-17 | Jeffrey T. Blue | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
| US9198977B2 (en) | 2012-01-30 | 2015-12-01 | Serum Institute Of India Ltd. | Immunogenic composition |
| KR102057217B1 (ko) | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
| PT2885007T (pt) * | 2012-08-16 | 2018-12-10 | Pfizer | Processos e composições de glicoconjugação |
| CN103893751B (zh) * | 2014-03-26 | 2016-04-20 | 天津康希诺生物技术有限公司 | 一种肺炎球菌多糖蛋白缀合疫苗及其制备方法 |
| US10729780B2 (en) * | 2015-06-08 | 2020-08-04 | Serum Institute Of India Private Ltd. | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof |
-
2016
- 2016-06-03 US US15/580,653 patent/US10729780B2/en active Active
- 2016-06-03 AU AU2016276269A patent/AU2016276269B2/en active Active
- 2016-06-03 KR KR1020237045298A patent/KR102876828B1/ko active Active
- 2016-06-03 EA EA201792470A patent/EA201792470A1/ru unknown
- 2016-06-03 CA CA2988366A patent/CA2988366C/en active Active
- 2016-06-03 MY MYPI2017704714A patent/MY187461A/en unknown
- 2016-06-03 CN CN201680040596.5A patent/CN107847571A/zh active Pending
- 2016-06-03 EP EP16806975.5A patent/EP3302542A4/en active Pending
- 2016-06-03 MX MX2017015985A patent/MX2017015985A/es unknown
- 2016-06-03 PE PE2017002539A patent/PE20180460A1/es unknown
- 2016-06-03 KR KR1020187000352A patent/KR102690378B1/ko active Active
- 2016-06-03 WO PCT/IB2016/053265 patent/WO2016199003A1/en not_active Ceased
- 2016-06-03 JP JP2017564108A patent/JP7258463B2/ja active Active
-
2017
- 2017-12-05 IL IL256118A patent/IL256118B/en unknown
- 2017-12-07 PH PH12017502244A patent/PH12017502244A1/en unknown
- 2017-12-07 ZA ZA2017/08325A patent/ZA201708325B/en unknown
- 2017-12-07 CO CONC2017/0012628A patent/CO2017012628A2/es unknown
- 2017-12-10 SA SA517390495A patent/SA517390495B1/ar unknown
-
2021
- 2021-08-06 JP JP2021129726A patent/JP2021185152A/ja active Pending
-
2024
- 2024-04-15 AU AU2024202450A patent/AU2024202450A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL256118A (en) | 2018-02-28 |
| AU2016276269B2 (en) | 2021-01-28 |
| KR20240007690A (ko) | 2024-01-16 |
| KR20180030498A (ko) | 2018-03-23 |
| MX2017015985A (es) | 2018-08-15 |
| NZ738090A (en) | 2023-09-29 |
| EP3302542A1 (en) | 2018-04-11 |
| US10729780B2 (en) | 2020-08-04 |
| WO2016199003A1 (en) | 2016-12-15 |
| IL256118B (en) | 2021-12-01 |
| JP7258463B2 (ja) | 2023-04-17 |
| PE20180460A1 (es) | 2018-03-06 |
| KR102876828B1 (ko) | 2025-10-27 |
| CA2988366C (en) | 2021-12-07 |
| JP2021185152A (ja) | 2021-12-09 |
| KR102690378B1 (ko) | 2024-08-01 |
| EP3302542A4 (en) | 2019-04-10 |
| CO2017012628A2 (es) | 2018-03-28 |
| BR112017026343A2 (pt) | 2019-11-19 |
| CA2988366A1 (en) | 2016-12-15 |
| PH12017502244A1 (en) | 2018-06-11 |
| MY187461A (en) | 2021-09-23 |
| JP2018516962A (ja) | 2018-06-28 |
| AU2024202450A1 (en) | 2024-10-31 |
| SA517390495B1 (ar) | 2023-03-23 |
| CN107847571A (zh) | 2018-03-27 |
| EA201792470A1 (ru) | 2018-10-31 |
| AU2016276269A1 (en) | 2018-01-18 |
| US20180161445A1 (en) | 2018-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL256118A (en) | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof | |
| IL265623A (en) | Multivalent vaccines for pneumonia that include polysaccharide-protein conjugates | |
| ZA201901346B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| ZA201708713B (en) | Multivalent pneumococcal conjugate vaccine | |
| IL268168A (en) | Immunogenic preparations for use as a vaccine against pneumococcus | |
| IL252915A0 (en) | Immunogenic preparations for use in pneumococcal vaccines | |
| ZA201801401B (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| HUE053332T2 (hu) | Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra | |
| SMT202400223T1 (it) | Coniugati comprendenti gruppi autoimmolativi e metodi correlati ad essi | |
| EP3142695A4 (en) | Compositions and methods of enhancing immunogenicity of polysaccharide-protein conjugates | |
| SG11201505889RA (en) | Multivalent glycoconjugate vaccines | |
| ZA201901345B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
| IL251120A0 (en) | Immunogenic/therapeutic glycoside preparations and their uses | |
| IL263218A (en) | Compounds and methods for microbiotic therapy | |
| ZA201608327B (en) | Curcumin-peptide conjugates and formulations thereof | |
| ZA201800928B (en) | Multivalent vlp conjugates | |
| GB201801566D0 (en) | Methods and compositions for nanormulsion vaccine formulations | |
| EP3703745A4 (en) | IMMUNOGENIC CONJUGATES AND METHOD OF USING THEREOF | |
| PT3297666T (pt) | Adjuvante e vacina molecular | |
| HK1258657A1 (en) | M hyo multivalent vaccine and uses thereof | |
| TH1701007335A (th) | วิธีการสำหรับการปรับปรุงการดูดซับของคอนจูเกตโพลีแซคคาไรด์-โปรตีน และ สูตรตำรับมัลติวาเลนท์วัคซีนที่ถูกได้มาจากสิ่งนั้น | |
| GB201712096D0 (en) | Immunogenic conjugates and use thereof | |
| GB201619946D0 (en) | Conjugated immunogenic derivatives and use thereof | |
| GB201410060D0 (en) | Multivalent and monovalent vaccines | |
| AU2014902031A0 (en) | Immunogenic vaccines and uses thereof |